We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$993M
AUM Growth
-$64.5M
Cap. Flow
-$14.1M
Cap. Flow %
-1.42%
Top 10 Hldgs %
99.96%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$13.7M
2
VOR icon
Vor Biopharma
VOR
+$456K
3
AMRN
Amarin Corp
AMRN
+$4.31K
4
RGLS
Regulus Therapeutics
RGLS
+$5

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$418M 42.1%
14,040,000
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$696M
$189M 19.02%
16,390,000
– –
BIIB icon
3
Biogen
BIIB
$30B
$131M 13.2%
643,000
– –
INVA icon
4
Innoviva
INVA
$1.55B
$97.6M 9.83%
6,614,000
– –
GILD icon
5
Gilead Sciences
GILD
$162B
$82.9M 8.35%
1,341,900
-221,000
-14% -$13.7M
AMRN
6
Amarin Corp
AMRN
$298M
$35.8M 3.6%
1,199,900
-100
-0% -$4.31K
MRSN
7
DELISTED
Mersana Therapeutics
MRSN
$19.9M 2%
171,972
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$14.7M 1.48%
1,390,790
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$3.07M 0.31%
30,900
-4,451
-13% -$456K
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$771K 0.08%
500,356
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$383K 0.04%
185,183
-2
-0% -$5

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sarissa Capital Management held 11 positions worth $993M, down 6.1% from $1.06B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 0%. Sarissa Capital Management opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's biggest Q2 2022 reduction was Gilead Sciences, cutting an estimated $13.7M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $993M portfolio in Q2 2022.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q2 2022.
  • Sarissa Capital Management's portfolio value fell 6.1% quarter-over-quarter to $993M.

Based on Sarissa Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.